Gdansk

• HIV: Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Ended
  2023-505900-53-00 4 2024-04-08 HIV infection
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended
  2023-505841-22-00 5 2024-04-04 Moderate to Severe Plaque Psoriasis
• A phase IIb study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis Ended
  2023-506477-35-00 4 2024-04-02 moderate to severe plaque psoriasis
• The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved eje … Ended
  2024-515061-33-00 5 2024-03-22 Depressive-anxiety states in people with heart failure with preserved
• A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arteri … Ended
  2022-502378-17-00 4 2024-03-20 Pulmonary Arterial Hypertension
• A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended
  2023-504955-28-01 4 2024-03-14 Sleep disturbances associated with menopause
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Ended
  2022-502713-29-00 5 2024-03-01 Dyskinesia due to cerebral palsy (DCP)
• A study to learn how effective and safe the drug “mirabegron” is and how long it stays in the body of children aged 6 months to less than 3 … Ended
  2023-507903-74-00 5 2024-02-28 Neurogenic detrusor overactivity (NDO)
• A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to te … Ended
  2022-502467-38-00 4 2024-02-22 Non-small cell lung cancer (NSCLC)
• This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu … Ended
  2023-504799-94-00 4 2024-02-20 Chronic Spontaneous Urticaria
• A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 … Ended
  2023-506354-20-00 1 2024-02-20 Small Cell Lung Cancer and Neuroendocrine Carcinoma
• Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended
  2023-504346-66-00 4 2024-02-14 Dermatitis atopic
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar … Ended
  2022-502484-38-00 5 2024-02-07 Type 2 diabetes
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A research study to see how a new weekly insulin, insulin icodec when given along with semaglutide helps in reducing the blood sugar level i … Ended
  2022-502717-28-00 5 2024-01-09 Diabetes Type 2
• Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended
  2023-503790-37-00 5 2024-01-09 Post-Menopausal Osteoporosis
• RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapy Ended
  2024-515131-30-00 4 2023-12-18 Relapsed / Refractory Metastatic or Advanced Solid Tumors
• A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended
  2022-502313-28-00 4 2023-12-14 Diabetic Peripheral Neuropathic Pain
• A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release … Ended
  2023-505296-72-00 4 2023-12-12 Idiopathic Pulmonary Fibrosis (IPF)
• A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and … Ended
  2023-503577-38-00 1 2023-12-07 Atopic Dermatitis

Showing 697–720 of 854 trials